Researchers from the University of Cincinnati Cancer Center are set to unveil significant advancements in oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago. Their presentations span a wide array of cutting-edge studies that push the boundaries of current cancer research—from adolescent and young adult (AYA) cancer survivorship to novel therapeutic approaches in acute myeloid leukemia (AML) and rare kidney cancers. These investigations delve deeply into the molecular landscapes, clinical challenges, and innovative treatments that could reshape patient care paradigms in oncology.
One of the forefront studies focuses on the unique population of adolescent and young adult (AYA) cancer survivors, individuals diagnosed between the ages of 18 and 39. This group has experienced rising cancer incidence rates over the past decade, yet their long-term health trajectories remain poorly understood. Led by oncologist and research scientist Alique Topalian, PhD, the investigation analyzes the baseline characteristics of AYA survivors receiving care in one of the nation’s few oncology primary care clinics specifically designed for cancer survivors. Utilizing a prospective clinical registry aimed at capturing longitudinal health outcomes, the team discovered that roughly 10% of the clinic’s patients were diagnosed during the AYA window.
Strikingly, 14% of these YAs had developed a second primary malignancy, underscoring an alarming predisposition for subsequent cancers in this demographic. Furthermore, cardiovascular diseases, particularly hypertension, affected about 60% of these patients, accompanied by frequent neurological, endocrine, and psychological comorbidities. Compounding these risks, lifestyle factors such as overweight and obesity prevailed in over half of the patients, with smoking histories—both former and current—adding to their vulnerability. Screening adherence varied, with breast cancer screening rates at 82%, colon cancer at 60%, and cervical cancer trailing at 40%. Topalian emphasizes the critical role oncology primary care providers must play in delivering comprehensive, lifelong monitoring and tailored preventative care to address the complex interplay of late effects and chronic conditions in this high-risk population.
Moving to hematologic malignancies, a separate investigation led by Eric Vick, MD, PhD, aims to quantify and characterize the overexpression of a protein isoform known as IRAK4L in acute myeloid leukemia (AML). Prior studies had recognized IRAK4L as hyperactive in AML cells, but precise expression levels and implications for chemotherapeutic resistance had remained elusive. By assessing animal models and patient-derived AML cell lines, Vick’s group demonstrated that most AML cancer cells express predominantly the IRAK4L isoform. When treated with azacitidine, a hypomethylating agent, and venetoclax, a targeted BCL-2 inhibitor, transient suppression of IRAK4L expression was observed. However, post-treatment recovery led to restoration of baseline protein levels, indicating that existing therapies only temporarily modulate this pro-tumorigenic pathway.
The implications of these findings extend to the development of next-generation pharmacologic inhibitors targeting IRAK4 as part of multifaceted therapeutic regimens. Vick anticipates that novel IRAK4 inhibitors may enter clinical trials imminently, presenting opportunities to overcome AML’s notorious ability to evade current treatment modalities. This research exemplifies the strategic shift toward precision medicine guided by molecular vulnerabilities inherent to specific leukemic subtypes.
Immunotherapy remains a dynamic frontier in oncology, highlighted by investigation into oncolytic viral therapies. The Phase 2 IGNYTE trial explores RP1, a genetically modified herpes simplex virus type 1 engineered to selectively infect and lyse tumor cells while stimulating systemic antitumor immunity. Under the guidance of Trisha Wise-Draper, MD, PhD, biosafety analyses of RP1’s behavior in patients with skin cancers revealed minimal viral dissemination beyond tumor sites. Detection of viral particles in blood, urine, and patient surfaces was negligible, with no secondary infections reported among close contacts or family members.
These safety data affirm that RP1’s replication remains tumor-restricted, a critical property to mitigate risks of contagion and systemic viral illness. Wise-Draper highlights that such reassuring biosafety profiles are essential for the continued evaluation of oncolytic viruses as viable immunotherapeutic agents. The ongoing trial aims to balance potent oncolytic activity with rigorous safety standards, setting the stage for broader incorporation of engineered viral platforms in oncology.
Another compelling study addresses the therapeutic void in adenoid cystic carcinoma (ACC), a rare, indolent yet treatment-resistant head and neck malignancy. Researchers under the mentorship of Wise-Draper initiated a Phase 2 clinical trial assessing amivantamab, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and MET pathways. Previously approved for lung cancer-resistant variants, amivantamab was evaluated for its potential to surmount ACC’s notorious drug resistance. Among the 21 enrolled patients, partial tumor responses were noted, with one case achieving a 30% reduction in lesion size. Additionally, 10 patients demonstrated stable disease, culminating in a clinical benefit rate of 61%.
Importantly, the therapeutic regimen was well tolerated, with side effects confined primarily to manageable infusion reactions and skin rashes. Patient-reported quality of life remained stable throughout treatment. Researchers plan to conduct extensive molecular profiling of tumor specimens to identify predictive biomarkers that may refine patient selection and optimize therapeutic efficacy. This work lays the foundation for future amivantamab combination trials or expanded enrollment to validate its role in ACC management.
In a groundbreaking advancement for rare pediatric and young adult kidney cancers, James I. Geller, MD, reports findings from the national Phase 2 AREN1721 trial targeting translocation renal cell carcinoma (tRCC). This aggressive neoplasm is driven by chromosomal rearrangements involving TFE3 or TFEB transcription factors, resulting in aberrant gene expression and unchecked tumor growth. The trial evaluated a novel combination therapy pairing nivolumab, an immune checkpoint inhibitor that invigorates antitumor T-cell responses, with axitinib, a tyrosine kinase inhibitor that disrupts tumor angiogenesis.
Though the study enrolled just 13 patients aged 7 to 42, outcomes were promising. The dual therapy extended median progression-free survival to 10.5 months, markedly outperforming nivolumab monotherapy, which yielded a median progression of 1.8 months. Approximately one-third of combination recipients experienced partial tumor regression, a feat not observed with single-agent immunotherapy. Adverse event profiles were consistent with known drug toxicities and presented no unexpected safety concerns. Geller underscores the significance of these results, signaling a pivotal step toward improved treatment paradigms for tRCC, although he stresses the necessity for continued clinical innovation.
Collectively, these diverse research initiatives highlight the University of Cincinnati Cancer Center’s commitment to advancing oncologic knowledge across age groups, cancer types, and therapeutic modalities. From elucidating the complex long-term health needs of AYA cancer survivors to pioneering molecularly guided treatments in intractable malignancies, the findings presented at ASCO 2025 portend a future in which personalized cancer care is not an aspiration but a standard. As cancer patients live longer and treatments evolve, multidisciplinary endeavors such as these ensure that survivorship and quality of life receive as much attention as disease eradication.
Emerging themes across these studies include the urgent necessity for longitudinal monitoring of high-risk populations, interdisciplinary collaboration bridging basic science and clinical practice, and regulatory frameworks that support innovative trial designs. Moreover, advances in molecular profiling and immune oncology herald an era where therapeutic resistance can be anticipated and circumvented rather than merely managed. These strides bring hope that tomorrow’s cancer treatments will be smarter, more effective, and tailored uniquely to each patient’s biology and experience.
The spotlight on adolescent and young adult oncology exemplifies a critical recalibration in the oncology community’s approach to survivorship. Tailored prevention, comprehensive primary care, and enhanced provider-patient education form the cornerstones of this evolving paradigm. Likewise, efforts to refine immunotherapies and targeted agents shown in trials of IRAK4 inhibitors, oncolytic viruses, and antibody-drug conjugates underscore a nuanced understanding of cancer’s molecular underpinnings and immune evasion tactics.
As the ASCO Annual Meeting convenes, the collective momentum fosters optimism and underscores the vibrancy of cancer research. The University of Cincinnati Cancer Center’s multifaceted contributions, spanning from bench to bedside, reflect the broader shift in oncology toward integration, precision, and compassionate care for all patients, regardless of age, cancer type, or stage.
—
Subject of Research: Oncology research encompassing adolescent and young adult cancer survivorship, acute myeloid leukemia molecular targets, oncolytic virus safety, rare head and neck cancer therapies, and novel treatments for rare kidney cancers.
Article Title: University of Cincinnati Cancer Center Unveils Pioneering Research at ASCO 2025: Advances in AYA Survivorship, AML Molecular Targets, and Novel Cancer Therapies
News Publication Date: May 2025
Web References:
– IGNYTE trial (NCT03767348) – https://clinicaltrials.gov/study/NCT03767348
Keywords: Oncology, Adolescent and Young Adult (AYA) Survivorship, Acute Myeloid Leukemia (AML), IRAK4L Protein, Oncolytic Virus, RP1, Amivantamab, Adenoid Cystic Carcinoma (ACC), Translocation Renal Cell Carcinoma (tRCC), Immunotherapy, Targeted Therapy, Nivolumab, Axitinib
